LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Article ; Online: Dose Finding for d-Serine Enhancement of Plasticity in Schizophrenia.

    Nemani, Katlyn / Goff, Donald C

    Biological psychiatry

    2023  Volume 94, Issue 2, Page(s) 106–107

    MeSH term(s) Humans ; Schizophrenia/drug therapy ; Serine
    Chemical Substances Serine (452VLY9402)
    Language English
    Publishing date 2023-06-26
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 209434-4
    ISSN 1873-2402 ; 0006-3223
    ISSN (online) 1873-2402
    ISSN 0006-3223
    DOI 10.1016/j.biopsych.2023.04.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Neuropsychiatric Complications after Stroke.

    Nemani, Katlyn / Gurin, Lindsey

    Seminars in neurology

    2021  Volume 41, Issue 1, Page(s) 85–100

    Abstract: Neuropsychiatric disturbances represent a common and uniquely challenging consequence of stroke. These disorders arise at the intersection of lesion-related brain dysfunction and psychological distress related to the event and its aftermath, making it ... ...

    Abstract Neuropsychiatric disturbances represent a common and uniquely challenging consequence of stroke. These disorders arise at the intersection of lesion-related brain dysfunction and psychological distress related to the event and its aftermath, making it difficult to identify what symptom is a direct physiological consequence of the stroke. Depression, anxiety, fatigue, apathy, emotionalism, and anger are the most common of these syndromes, and posttraumatic stress disorder related to the stroke event has become increasingly recognized as a relevant entity. Mania, obsessive-compulsive disorder, and psychosis are less commonly encountered but potentially highly debilitating conditions that may be underrecognized. Early identification and treatment may mitigate functional impairment and improve quality of life. Evidence-based guidelines from the general population are often relied upon to guide treatment. Further research is needed to understand and tailor treatment of these disorders in the poststroke population.
    MeSH term(s) Fatigue ; Humans ; Quality of Life ; Stroke/complications
    Language English
    Publishing date 2021-01-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603165-1
    ISSN 1098-9021 ; 0271-8235
    ISSN (online) 1098-9021
    ISSN 0271-8235
    DOI 10.1055/s-0040-1722723
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Neuropsychiatric Complications after Stroke

    Nemani, Katlyn / Gurin, Lindsey

    Seminars in Neurology

    (Acute Stroke)

    2021  Volume 41, Issue 01, Page(s) 85–100

    Abstract: Neuropsychiatric disturbances represent a common and uniquely challenging consequence of stroke. These disorders arise at the intersection of lesion-related brain dysfunction and psychological distress related to the event and its aftermath, making it ... ...

    Series title Acute Stroke
    Abstract Neuropsychiatric disturbances represent a common and uniquely challenging consequence of stroke. These disorders arise at the intersection of lesion-related brain dysfunction and psychological distress related to the event and its aftermath, making it difficult to identify what symptom is a direct physiological consequence of the stroke. Depression, anxiety, fatigue, apathy, emotionalism, and anger are the most common of these syndromes, and posttraumatic stress disorder related to the stroke event has become increasingly recognized as a relevant entity. Mania, obsessive–compulsive disorder, and psychosis are less commonly encountered but potentially highly debilitating conditions that may be underrecognized. Early identification and treatment may mitigate functional impairment and improve quality of life. Evidence-based guidelines from the general population are often relied upon to guide treatment. Further research is needed to understand and tailor treatment of these disorders in the poststroke population.
    Keywords stroke ; neuropsychiatry ; poststroke depression ; anxiety ; posttraumatic stress disorder ; fatigue ; apathy ; emotionalism ; anger ; psychosis
    Language English
    Publishing date 2021-01-28
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 603165-1
    ISSN 1098-9021 ; 0271-8235
    ISSN (online) 1098-9021
    ISSN 0271-8235
    DOI 10.1055/s-0040-1722723
    Database Thieme publisher's database

    More links

    Kategorien

  4. Article ; Online: Association Between Antipsychotic Use and COVID-19 Mortality Among People With Serious Mental Illness.

    Nemani, Katlyn / Conderino, Sarah / Marx, Julia / Thorpe, Lorna E / Goff, Donald C

    JAMA psychiatry

    2021  Volume 78, Issue 12, Page(s) 1391–1393

    MeSH term(s) Adult ; Aged ; Antipsychotic Agents/adverse effects ; Bipolar Disorder/drug therapy ; COVID-19/mortality ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; SARS-CoV-2 ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents
    Language English
    Publishing date 2021-09-22
    Publishing country United States
    Document type Letter
    ZDB-ID 2701203-7
    ISSN 2168-6238 ; 2168-622X
    ISSN (online) 2168-6238
    ISSN 2168-622X
    DOI 10.1001/jamapsychiatry.2021.2503
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Finding cancer at home.

    Nemani, Katlyn L

    The American journal of managed care

    2010  Volume 16, Issue 12 Suppl HIT, Page(s) e330–2

    MeSH term(s) Attitude of Health Personnel ; Carcinogens ; Cluster Analysis ; Electronic Health Records ; Environmental Exposure/adverse effects ; Female ; Hodgkin Disease/diagnosis ; Hodgkin Disease/epidemiology ; Hodgkin Disease/etiology ; Hodgkin Disease/psychology ; Humans ; New Hampshire ; Young Adult
    Chemical Substances Carcinogens
    Language English
    Publishing date 2010-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2035781-3
    ISSN 1936-2692 ; 1088-0224 ; 1096-1860
    ISSN (online) 1936-2692
    ISSN 1088-0224 ; 1096-1860
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Association of Psychiatric Disorders With Mortality Among Patients With COVID-19.

    Nemani, Katlyn / Li, Chenxiang / Olfson, Mark / Blessing, Esther M / Razavian, Narges / Chen, Ji / Petkova, Eva / Goff, Donald C

    JAMA psychiatry

    2021  Volume 78, Issue 4, Page(s) 380–386

    Abstract: Importance: To date, the association of psychiatric diagnoses with mortality in patients infected with coronavirus disease 2019 (COVID-19) has not been evaluated.: Objective: To assess whether a diagnosis of a schizophrenia spectrum disorder, mood ... ...

    Abstract Importance: To date, the association of psychiatric diagnoses with mortality in patients infected with coronavirus disease 2019 (COVID-19) has not been evaluated.
    Objective: To assess whether a diagnosis of a schizophrenia spectrum disorder, mood disorder, or anxiety disorder is associated with mortality in patients with COVID-19.
    Design, setting, and participants: This retrospective cohort study assessed 7348 consecutive adult patients for 45 days following laboratory-confirmed COVID-19 between March 3 and May 31, 2020, in a large academic medical system in New York. The final date of follow-up was July 15, 2020. Patients without available medical records before testing were excluded.
    Exposures: Patients were categorized based on the following International Statistical Classification of Diseases, Tenth Revision, Clinical Modification diagnoses before their testing date: (1) schizophrenia spectrum disorders, (2) mood disorders, and (3) anxiety disorders. Patients with these diagnoses were compared with a reference group without psychiatric disorders.
    Main outcomes and measures: Mortality, defined as death or discharge to hospice within 45 days following a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result.
    Results: Of the 26 540 patients tested, 7348 tested positive for SARS-CoV-2 (mean [SD] age, 54 [18.6] years; 3891 [53.0%] women). Of eligible patients with positive test results, 75 patients (1.0%) had a history of a schizophrenia spectrum illness, 564 (7.7%) had a history of a mood disorder, and 360 (4.9%) had a history of an anxiety disorder. After adjusting for demographic and medical risk factors, a premorbid diagnosis of a schizophrenia spectrum disorder was significantly associated with mortality (odds ratio [OR], 2.67; 95% CI, 1.48-4.80). Diagnoses of mood disorders (OR, 1.14; 95% CI, 0.87-1.49) and anxiety disorders (OR, 0.96; 95% CI, 0.65-1.41) were not associated with mortality after adjustment. In comparison with other risk factors, a diagnosis of schizophrenia ranked behind only age in strength of an association with mortality.
    Conclusions and relevance: In this cohort study of adults with SARS-CoV-2-positive test results in a large New York medical system, adults with a schizophrenia spectrum disorder diagnosis were associated with an increased risk for mortality, but those with mood and anxiety disorders were not associated with a risk of mortality. These results suggest that schizophrenia spectrum disorders may be a risk factor for mortality in patients with COVID-19.
    MeSH term(s) Anxiety Disorders/diagnosis ; Anxiety Disorders/epidemiology ; COVID-19/mortality ; COVID-19/therapy ; Comorbidity ; Female ; Humans ; International Classification of Diseases ; Male ; Middle Aged ; Mood Disorders/diagnosis ; Mood Disorders/epidemiology ; Mortality ; New York/epidemiology ; Retrospective Studies ; Risk Assessment ; Risk Factors ; SARS-CoV-2/isolation & purification ; Schizophrenia/diagnosis ; Schizophrenia/epidemiology
    Language English
    Publishing date 2021-02-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2701203-7
    ISSN 2168-6238 ; 2168-622X
    ISSN (online) 2168-6238
    ISSN 2168-622X
    DOI 10.1001/jamapsychiatry.2020.4442
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System.

    Nemani, Katlyn / Williams, Sharifa Z / Olfson, Mark / Leckman-Westin, Emily / Finnerty, Molly / Kammer, Jammie / Smith, Thomas E / Silverman, Daniel J / Lindenmayer, Jean-Pierre / Capichioni, Gillian / Clelland, James / Goff, Donald C

    JAMA network open

    2022  Volume 5, Issue 5, Page(s) e2210743

    Abstract: Importance: Individuals with serious mental illness are at increased risk of severe COVID-19 infection. Several psychotropic medications have been identified as potential therapeutic agents to prevent or treat COVID-19 but have not been systematically ... ...

    Abstract Importance: Individuals with serious mental illness are at increased risk of severe COVID-19 infection. Several psychotropic medications have been identified as potential therapeutic agents to prevent or treat COVID-19 but have not been systematically examined in this population.
    Objective: To evaluate the associations between the use of psychotropic medications and the risk of COVID-19 infection among adults with serious mental illness receiving long-term inpatient psychiatric treatment.
    Design, setting, and participants: This retrospective cohort study assessed adults with serious mental illness hospitalized in a statewide psychiatric hospital system in New York between March 8 and July 1, 2020. The final date of follow-up was December 1, 2020. The study included 1958 consecutive adult inpatients with serious mental illness (affective or nonaffective psychoses) who received testing for SARS-CoV-2 by reverse transcriptase-polymerase chain reaction or antinucleocapsid antibodies and were continuously hospitalized from March 8 until medical discharge or July 1, 2020.
    Exposures: Psychotropic medications prescribed prior to COVID-19 testing.
    Main outcomes and measures: COVID-19 infection was the primary outcome, defined by a positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction or antibody test result. The secondary outcome was COVID-19-related death among patients with laboratory-confirmed infection.
    Results: Of the 2087 adult inpatients with serious mental illness continuously hospitalized during the study period, 1958 (93.8%) underwent testing and were included in the study; 1442 (73.6%) were men, and the mean (SD) age was 51.4 (14.3) years. A total of 969 patients (49.5%) had laboratory-confirmed COVID-19 infection that occurred while they were hospitalized; of those, 38 (3.9%) died. The use of second-generation antipsychotic medications, as a class, was associated with decreased odds of infection (odds ratio [OR], 0.62; 95% CI, 0.45-0.86), whereas the use of mood stabilizers was associated with increased odds of infection (OR, 1.23; 95% CI, 1.03-1.47). In a multivariable model of individual medications, the use of paliperidone was associated with decreased odds of infection (OR, 0.59; 95% CI, 0.41-0.84), and the use of valproic acid was associated with increased odds of infection (OR, 1.39; 95% CI, 1.10-1.76). Clozapine use was associated with reduced odds of mortality in unadjusted analyses (unadjusted OR, 0.25; 95% CI, 0.10-0.62; fully adjusted OR, 0.43; 95% CI, 0.17-1.12).
    Conclusions and relevance: In this cohort study of adults hospitalized with serious mental illness, the use of second-generation antipsychotic medications was associated with decreased risk of COVID-19 infection, whereas the use of valproic acid was associated with increased risk. Further research is needed to assess the mechanisms that underlie these findings.
    MeSH term(s) Adult ; Antipsychotic Agents/adverse effects ; COVID-19/epidemiology ; COVID-19 Testing ; Cohort Studies ; Female ; Hospitals, Psychiatric ; Humans ; Inpatients ; Male ; Mental Disorders/drug therapy ; Mental Disorders/epidemiology ; Middle Aged ; New York/epidemiology ; Psychotropic Drugs/adverse effects ; RNA-Directed DNA Polymerase ; Retrospective Studies ; SARS-CoV-2 ; Valproic Acid
    Chemical Substances Antipsychotic Agents ; Psychotropic Drugs ; Valproic Acid (614OI1Z5WI) ; RNA-Directed DNA Polymerase (EC 2.7.7.49)
    Language English
    Publishing date 2022-05-02
    Publishing country United States
    Document type Journal Article
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2022.10743
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Schizophrenia and the gut-brain axis.

    Nemani, Katlyn / Hosseini Ghomi, Reza / McCormick, Beth / Fan, Xiaoduo

    Progress in neuro-psychopharmacology & biological psychiatry

    2015  Volume 56, Page(s) 155–160

    Abstract: Several risk factors for the development of schizophrenia can be linked through a common pathway in the intestinal tract. It is now increasingly recognized that bidirectional communication exists between the brain and the gut that uses neural, hormonal, ... ...

    Abstract Several risk factors for the development of schizophrenia can be linked through a common pathway in the intestinal tract. It is now increasingly recognized that bidirectional communication exists between the brain and the gut that uses neural, hormonal, and immunological routes. An increased incidence of gastrointestinal (GI) barrier dysfunction, food antigen sensitivity, inflammation, and the metabolic syndrome is seen in schizophrenia. These findings may be influenced by the composition of the gut microbiota. A significant subgroup of patients may benefit from the initiation of a gluten and casein-free diet. Antimicrobials and probiotics have therapeutic potential for reducing the metabolic dysfunction and immune dysregulation seen in patients with schizophrenia.
    MeSH term(s) Anti-Infective Agents/therapeutic use ; Brain/physiopathology ; Gastrointestinal Tract/microbiology ; Humans ; Microbiota/physiology ; Schizophrenia/drug therapy ; Schizophrenia/pathology
    Chemical Substances Anti-Infective Agents
    Language English
    Publishing date 2015-01-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 781181-0
    ISSN 1878-4216 ; 0278-5846
    ISSN (online) 1878-4216
    ISSN 0278-5846
    DOI 10.1016/j.pnpbp.2014.08.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis.

    Fond, Guillaume / Nemani, Katlyn / Etchecopar-Etchart, Damien / Loundou, Anderson / Goff, Donald C / Lee, Seung Won / Lancon, Christophe / Auquier, Pascal / Baumstarck, Karine / Llorca, Pierre-Michel / Yon, Dong Keon / Boyer, Laurent

    JAMA psychiatry

    2021  Volume 78, Issue 11, Page(s) 1208–1217

    Abstract: Importance: Heterogeneous evidence exists for the association between COVID-19 and the clinical outcomes of patients with mental health disorders. It remains unknown whether patients with COVID-19 and mental health disorders are at increased risk of ... ...

    Abstract Importance: Heterogeneous evidence exists for the association between COVID-19 and the clinical outcomes of patients with mental health disorders. It remains unknown whether patients with COVID-19 and mental health disorders are at increased risk of mortality and should thus be targeted as a high-risk population for severe forms of COVID-19.
    Objective: To determine whether patients with mental health disorders were at increased risk of COVID-19 mortality compared with patients without mental health disorders.
    Data sources: For this systematic review and meta-analysis, MEDLINE, Web of Science, and Google Scholar were searched from inception to February 12, 2021. Bibliographies were also searched, and the corresponding authors were directly contacted. The search paradigm was based on the following combination: (mental, major[MeSH terms]) AND (COVID-19 mortality[MeSH terms]). To ensure exhaustivity, the term mental was replaced by psychiatric, schizophrenia, psychotic, bipolar disorder, mood disorders, major depressive disorder, anxiety disorder, personality disorder, eating disorder, alcohol abuse, alcohol misuse, substance abuse, and substance misuse.
    Study selection: Eligible studies were population-based cohort studies of all patients with identified COVID-19 exploring the association between mental health disorders and mortality.
    Data extraction and synthesis: Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was used for abstracting data and assessing data quality and validity. This systematic review is registered with PROSPERO.
    Main outcomes and measures: Pooled crude and adjusted odds ratios (ORs) for the association of mental health disorders with mortality were calculated using a 3-level random-effects (study/country) approach with a hierarchical structure to assess effect size dependency.
    Results: In total, 16 population-based cohort studies (data from medico-administrative health or electronic/medical records databases) across 7 countries (1 from Denmark, 2 from France, 1 from Israel, 3 from South Korea, 1 from Spain, 1 from the UK, and 7 from the US) and 19 086 patients with mental health disorders were included. The studies covered December 2019 to July 2020, were of good quality, and no publication bias was identified. COVID-19 mortality was associated with an increased risk among patients with mental health disorders compared with patients without mental health disorders according to both pooled crude OR (1.75 [95% CI, 1.40-2.20]; P < .05) and adjusted OR (1.38 [95% CI, 1.15-1.65]; P < .05). The patients with severe mental health disorders had the highest ORs for risk of mortality (crude OR: 2.26 [95% CI, 1.18-4.31]; adjusted OR: 1.67 [95% CI, 1.02-2.73]).
    Conclusions and relevance: In this systematic review and meta-analysis of 16 observational studies in 7 countries, mental health disorders were associated with increased COVID-19-related mortality. Thus, patients with mental health disorders should have been targeted as a high-risk population for severe forms of COVID-19, requiring enhanced preventive and disease management strategies. Future studies should more accurately evaluate the risk for patients with each mental health disorder. However, the highest risk seemed to be found in studies including individuals with schizophrenia and/or bipolar disorders.
    MeSH term(s) COVID-19/mortality ; COVID-19/therapy ; Comorbidity ; Humans ; Mental Disorders/epidemiology
    Language English
    Publishing date 2021-07-27
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 2701203-7
    ISSN 2168-6238 ; 2168-622X
    ISSN (online) 2168-6238
    ISSN 2168-622X
    DOI 10.1001/jamapsychiatry.2021.2274
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder.

    Nemani, Katlyn L / Greene, M Claire / Ulloa, Melissa / Vincenzi, Brenda / Copeland, Paul M / Al-Khadari, Sulaiman / Henderson, David C

    Clinical schizophrenia & related psychoses

    2017  Volume 12, Issue 4, Page(s) 168–176

    Abstract: The goal of this 21-year naturalistic study of clozapine-treated patients was to examine the cardiovascular risk factors following clozapine initiation and resultant mortality estimates from cardiovascular disease. Data were collected from January 1992 ... ...

    Abstract The goal of this 21-year naturalistic study of clozapine-treated patients was to examine the cardiovascular risk factors following clozapine initiation and resultant mortality estimates from cardiovascular disease. Data were collected from January 1992 to February 2012 medical records from clozapine-treated patients with schizophrenia or schizoaffective disorder. Demographics, clozapine dosage and laboratory results were extracted at 12-month intervals. At clozapine initiation, the mean age of the 96 patients was 36.4 years±7.6 years; n=27 (28%) were women. The mean duration of clozapine use was 13 years. The Kaplan-Meier estimate for 21-year cardiovascular events was 29%, while the Kaplan-Meier estimate for 21-year mortality from cardiovascular disease was 10%. The mean cardiovascular risk increased during the first ten years (p<.01), while a slight decrease occurred beyond ten years (p<.01). Patients involved in cardiometabolic research showed a greater decrease in cardiovascular risk factors over 21 years (p=.05). The Kaplan-Meier estimate for 21-year all-cause mortality was 22%. Forty-one patients were diagnosed with diabetes (42.7%), compared to a nationwide prevalence of 13.7% in a similar age group. These results support the hypothesis that clozapine-treated patients are at risk for cardiovascular events and death secondary to an increased risk of medical disorders. Interventions that target weight loss, smoking cessation, and lipid profile improvement may alleviate the increased risk of cardiovascular mortality.
    MeSH term(s) Adult ; Antipsychotic Agents/adverse effects ; Cardiovascular Diseases/chemically induced ; Clozapine/adverse effects ; Diabetes Mellitus/chemically induced ; Female ; Humans ; Male ; Psychotic Disorders/drug therapy ; Risk Factors ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Clozapine (J60AR2IKIC)
    Language English
    Publishing date 2017-11-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2489256-7
    ISSN 1941-2010 ; 1935-1232
    ISSN (online) 1941-2010
    ISSN 1935-1232
    DOI 10.3371/CSRP.KNMG.111717
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top